Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT00445939

A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease

Sponsor: Abbott

Conditions Crohn's Disease

Interventions adalimumab placebo

Updated 7 times since 2017 Last updated: Jun 20, 2011 Started: Feb 28, 2007 Primary completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Crohn's Disease, this trial is completed. The trial is conducted by Abbott and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Abbott Japan Co.,Ltd
Eisai Co., Ltd.

Data source: Abbott

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Chiba, Japan , Ehime, Japan , Fukuoka, Japan , Hiroshima, Japan , Hokkaido, Japan , Hyōgo, Japan , Kagawa, Japan , Kanagawa, Japan , Kochi, Japan and 8 more locations